Thymosin Alpha-1 (Tα1) Subcutaneous Research Dosing Protocol
-
For research use only. Not medical advice.
Overview
Thymosin Alpha-1 is a 28–amino-acid immunomodulatory peptide studied for its ability to enhance innate and adaptive immune responses.
Research applications commonly focus on immune resilience, antiviral support, and inflammation regulation.Daily Dosing Protocol (Subcutaneous)
Standard Daily Range
300–1000 mcg three times a week
Titration Schedule
Week 1 - 4
300-1000 mcg 3 days a week
Used to assess tolerability and early immune response.
This is the most common working dose across immune-focused research models.
Timing
Timing is flexible; some researchers prefer morning dosing to align with immune signaling during waking hours.
Cycle Length
Common Thymosin Alpha-1 research cycles:
3–4 weeks, depending on the immune model
Optional 2–4 week break before repeating
Common Research Notes
Tα1 is generally well tolerated; transient injection-site redness or mild flu-like sensations can occur early and usually resolve.
Effects are cumulative and typically assessed over several weeks rather than days.
Often stacked with antioxidants or mitochondrial support agents in immune-resilience protocols.
Unlike general stimulants, Tα1 modulates immune signaling rather than simply increasing activity.
-
Im doing 3x a week and 1mg in the winter season and daily 3 days before a flight or trip.
I will use use this forever.
